PROCEPT BioRobotics (PRCT) news
Recent news
Procept Biorobotics Corp: Leerink Partners cuts target price to $21 from $29
Leerink Partners has revised its target price for Procept Biorobotics Corp (PRCT) from $29 to $21, maintaining a "Hold" rating for the stock. The downgrade reflects ongoing challenges in the company’s operational performance and market dynamics. PRCT, a commercial-stage surgical robotics firm,…
AInvest Wire · Aug 5, 2026PRCT still sees FY gross margin about 65%, est. 65.3%
Procept Biorobotics Corp (PRCT) is projected to maintain a gross margin of approximately 65% for fiscal year 2026, with estimates placing it at around 65.3% . This anticipated margin reflects continued improvements in overhead absorption and a favorable revenue mix, particularly from U.S. handpiece…
AInvest Wire · Aug 4, 2026PRCT still sees FY revenue $390M to $410M, estimated $398M
AInvest Wire · Aug 4, 2026Procept Biorobotics outlook FY revenue USD 390-410 million
AInvest Wire · Aug 4, 2026Procept Biorobotics Corp - expects FY2026 U.S. procedure volume of 54,000-56,000, up 25%-29%
AInvest Wire · Aug 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.